Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases... Show more
The 50-day moving average for ARGX moved above the 200-day moving average on August 29, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ARGX advanced for three days, in of 298 cases, the price rose further within the following month. The odds of a continued upward trend are .
ARGX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In of 242 cases where ARGX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The 10-day RSI Indicator for ARGX moved out of overbought territory on September 16, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 similar instances where the indicator moved out of overbought territory. In of the 29 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on September 18, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on ARGX as a result. In of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for ARGX turned negative on September 16, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARGX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ARGX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.407) is normal, around the industry mean (19.929). P/E Ratio (37.551) is within average values for comparable stocks, (54.169). Projected Growth (PEG Ratio) (1.274) is also within normal values, averaging (2.181). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (16.502) is also within normal values, averaging (352.599).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
a manufacturer of antibody-based medicines
Industry Biotechnology
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
BEGS | 38.74 | 2.18 | +5.96% |
Rareview 2X Bull Cryptoccy & Prc Mtl ETF | |||
FNGG | 242.88 | 0.77 | +0.32% |
Direxion Daily NYSE FANG+ Bull 2X Shares | |||
BME | 36.32 | 0.10 | +0.28% |
Blackrock Health Sciences Trust | |||
EUFN | 34.16 | 0.02 | +0.06% |
iShares MSCI Europe Financials ETF | |||
FMNY | 26.46 | -0.03 | -0.11% |
First Trust New York High Inc Mncpl ETF |
A.I.dvisor indicates that over the last year, ARGX has been loosely correlated with ARGNF. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if ARGX jumps, then ARGNF could also see price increases.
Ticker / NAME | Correlation To ARGX | 1D Price Change % | ||
---|---|---|---|---|
ARGX | 100% | +1.04% | ||
ARGNF - ARGX | 55% Loosely correlated | N/A | ||
ALNY - ARGX | 41% Loosely correlated | +0.24% | ||
AXON - ARGX | 40% Loosely correlated | +1.01% | ||
APLS - ARGX | 38% Loosely correlated | +1.25% | ||
ARRY - ARGX | 36% Loosely correlated | -2.30% | ||
More |